Tyrosine receptor kinase B is a drug target in astrocytomas

Conclusions. Our findings provide evidence that constitutively activated NTRK2 alleles, notably the human tumor-associated QKI-NTRK2 fusion, can cooperate with Ink4a/Arf loss to drive astrocytoma formation. Therefore, we propose NTRK2 as a potential therapeutic target in the subset of astrocytoma patients defined by QKI-NTRK2 fusion.
Source: Neuro-Oncology - Category: Cancer & Oncology Authors: Tags: Basic and Translational Investigations Source Type: research